BACKGROUND: Experimentally, metalloproteinases (MMPs) play a detrimental role related to the severity of @entity75 . Both MMPs activity and function in tissues reflect the balance between MMPs and tissue inhibitors of metalloproteinases (TIMPs). We aimed to evaluate the role of MMPs/TIMPs balance in the setting of rtPA-treated @entity64 @entity1 . METHODS: Blood was taken before and 24-h after rtPA from 327 @entity1 (mean age 68 years, median NIHSS 11) with acute @entity385 . Delta median values of each MMP/ @entity2843 ratio [(post rtPA MMP/ @entity2843 -baseline MMP/ @entity2843 )/(baseline MMP/ @entity2843 )] were analyzed related to symptomatic @entity932 (sICH) according to NINDS criteria, relevant @entity548 ( @entity548 ) defined as confluent petechiae within the infarcted area or any @entity548 , @entity64 subtypes (according to Oxfordshire @entity64 Project) and 3-month @entity204 . The net effect of each MMP/ @entity2843 ratio was estimated by a logistic regression model including major clinical determinants of outcomes. RESULTS: Adjusting for major clinical determinants, only increase in @entity1495 / @entity2843 and @entity1495 / @entity1552 ratios remained significantly associated with sICH (odds ratio [95% confidence interval], 1.67 [1.17-2.38], p   =   0.005; 1.74 [1.21-2.49], p   =   0.003, respectively). Only relative increase in @entity1495 / @entity2843 ratio proved significantly associated with relevant @entity548 (odds ratio [95% confidence interval], 1.74 [1.17-2.57], p   =   0.006) with a trend toward significance for @entity1495 / @entity1552 ratio (p   =   0.007). DISCUSSION: Our data add substantial clinical evidence about the role of MMPs/TIMPs balance in rtPA-treated @entity64 @entity1 . These results may serve to generate hypotheses on MMPs inhibitors to be administered together with rtPA in order to counteract its deleterious effect.

Unbalanced Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases Ratios Predict @entity548 in @entity385 XXXX Treated with Thrombolysis: Results from the MAGIC Study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1552 :: ('7077', 'Gene') :: ['TIMP2'] @entity64 :: ('MESH:D020521', 'Disease') :: ['Community Stroke', 'stroke'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage'] @entity548 :: ('MESH:D006470', 'Disease') :: ['parenchymal hemorrhage', 'HT', 'hemorrhagic transformation'] @entity75 :: ('MESH:D001927', 'Disease') :: ['ischemic brain lesions'] @entity2843 :: ('7076', 'Gene') :: ['TIMP', 'TIMP1'] @entity1495 :: ('4318', 'Gene') :: ['MMP9'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity1 :: (9606,Species) :: ['Patients']
